These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 34516943)

  • 21. The Marketing Firm and the Consumer Organization: A Comparative Analysis With Special Reference to Charitable Organizations.
    Foxall GR; Sigurdsson V; Gallogly JK
    Front Psychol; 2020; 11():535793. PubMed ID: 33324273
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An economic model of multi-level marketing.
    Reingewertz Y
    PLoS One; 2021; 16(7):e0253700. PubMed ID: 34283856
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The spillover effects of China's regional environmental markets to local listed firms: a risk Granger causality approach.
    Zhu S; Tang Y; Qiao X; Peng C; Li D
    Environ Sci Pollut Res Int; 2020 Dec; 27(35):44123-44136. PubMed ID: 32761345
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The impact of price-cap regulations on market entry by generic pharmaceutical firms.
    Zhang W; Sun H; Guh D; Anis AH
    Expert Rev Pharmacoecon Outcomes Res; 2017 Apr; 17(2):231-238. PubMed ID: 27936981
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A comparative study of internal customer management practices within service sector firms and the National Health Service.
    Chaston I
    J Adv Nurs; 1994 Feb; 19(2):299-308. PubMed ID: 8188961
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Are Health Insurance Markets Competitive?
    Dafny LS
    Am Econ Rev; 2010 Sep; 100(4):1399-431. PubMed ID: 29517879
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Points to consider about prescription drug prices: an overview of federal policy and pricing studies.
    Kucukarslan S; Hakim Z; Sullivan D; Taylor S; Grauer D; Haugtvedt C; Zgarrick D
    Clin Ther; 1993; 15(4):726-38. PubMed ID: 8221823
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Assistive technology pricing in Australia: is it efficient and equitable?
    Summers MP; Verikios G
    Aust Health Rev; 2018 Feb; 42(1):100-110. PubMed ID: 28160784
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Community responses to national healthcare firms.
    Wholey DR; Christianson JB; Draper DA; Lesser CS; Burns LR
    J Health Soc Behav; 2004; 45 Suppl():118-35. PubMed ID: 15779470
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Equilibrium pricing and ordering policies in a two-echelon supply chain in the presence of strategic customers.
    Sadjadi SJ; Naeij J; Shavandi H; Makui A
    An Acad Bras Cienc; 2016 Jun; 88(2):1127-50. PubMed ID: 27276375
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Transportation price, product differentiation, and R&D in an oligopoly.
    Kanehara D; Kamei K
    PLoS One; 2022; 17(9):e0273904. PubMed ID: 36083876
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Price competition in pharmaceuticals - Evidence from 1303 Swedish markets.
    Granlund D; Bergman MA
    J Health Econ; 2018 Sep; 61():1-12. PubMed ID: 30007260
    [TBL] [Abstract][Full Text] [Related]  

  • 33. How does managed competition affect hospital prices in a social health insurance system? The Colombian case.
    Fernando R; Leticia AB; Antonio J T
    Health Policy Plan; 2018 Nov; 33(9):1037-1046. PubMed ID: 30462221
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Micro-Level Adaptation, Macro-Level Selection, and the Dynamics of Market Partitioning.
    García-Díaz C; van Witteloostuijn A; Péli G
    PLoS One; 2015; 10(12):e0144574. PubMed ID: 26656107
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evolutionary technology adoption in an oligopoly market with forward-looking firms.
    Lamantia F; Radi D
    Chaos; 2018 May; 28(5):055904. PubMed ID: 29857662
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An empirical analysis of the multimarket contact theory in pharmaceutical markets.
    Coronado J; Jiménez-Martín S; Marín PL
    Eur J Health Econ; 2014 Jul; 15(6):623-43. PubMed ID: 23818281
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The consumer welfare implications of governmental policies and firm strategy in markets for medicines.
    Chatterjee C; Kubo K; Pingali V
    J Health Econ; 2015 Dec; 44():255-73. PubMed ID: 26581076
    [TBL] [Abstract][Full Text] [Related]  

  • 38. When to ally & when to acquire.
    Dyer JH; Kale P; Singh H
    Harv Bus Rev; 2004; 82(7-8):108-15, 188. PubMed ID: 15241957
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Buyer and seller data from pay what you want and name your own price laboratory markets.
    Krämer F; Schmidt KM; Spann M; Stich L
    Data Brief; 2017 Jun; 12():513-517. PubMed ID: 28516147
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Watch your neighbor: Strategic competition in waste collection and service quality.
    Bel G; Sebő M
    Waste Manag; 2021 May; 127():63-72. PubMed ID: 33930686
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.